CBIA Canopus Biopharma Inc (PK)

Canopus BioPharma, Inc. (OTCPK: CBIA), a biotechnology company developing pharmaceutical products and assay methods for patients suffering from infectious disease, radiation sickness, cancer, and addiction, announced today that it has engaged Pullan Consulting to identify and enter into drug development and licensing partnerships with large pharmaceutical companies. Pullan Consulting is a California-based biotech business development consulting firm led by Linda Pullan, Ph.D., which has served over 20 emerging and later stage pharmaceutical companies since being established in 2006. Dr. Linda Pullan has more than 20 years of experience in the pharma and biotech industry. Prior to forming Pullan Consulting (www.pullanconsulting.com), she was Vice President of Business Development of Kosan Biosciences, head of oncology and hematology licensing at Amgen,�collaborations manager�at what is now AstraZeneca, and in drug discovery research at what is now Pfizer. She gained her Ph.D. in Biochemistry from the University of California at Riverside, and BS in Chemistry from the University of Utah. She has authored 66 publications. Her deal sheet lists 8 major deals and more than 10 others. �We are pleased to have engaged Pullan Consulting as it marks the commencement of the next phase of our business plan, which is to enter into drug development and licensing partnerships,� said Canopus BioPharma�s Chairman and Chief Executive Officer Patrick Prendergast. �Linda Pullan, Ph.D. has a proven track record of success in drug development, valuation analysis and negotiation for strategic alliances and licensing deals. With very relevant experience relating to our broad portfolio of drug candidates targeting large markets, we believe our collaboration will help accelerate the development of drugs which are important to the improvement of healthcare around the world.� �I�m delighted to have the chance to work with Canopus BioPharma, and their diverse portfolio of partnerable opportunities, many of which are at clinical stages,� commented Linda Pullan. About Canopus BioPharma, Inc.: Canopus BioPharma, Inc. (OTCPK: CBIA) is dedicated to providing the safest, most cost effective and efficacious pharmaceutical products and assay methods to patients suffering from infectious disease, bio-terrorism, cancer, and addiction. With innovative science, proven research and development leadership, and superior products and compounds, Canopus BioPharma has since 2001 been committed to becoming a market trend setter in the new era of healthcare, which is focused on providing affordable therapeutic and diagnostic benefits and pharmaceutical excellence to patients and healthcare professionals worldwide. In addition, the Company is a world leader in the development of novel camelid antibody products to provide unique avenues of progress and improvement in assay methods and monitoring capabilities for physicians, patients and researchers, particularly for food chain protection applications. Canopus maintains staff in Australia, South Africa, Ireland, Panama and the USA. Additional information on the Company is available at www.canopusbiopharma.com. With the exception of historical information contained in this press release, content herein may contain �forward looking statements� that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management�s current expectations and are subject to uncertainty and changes in circumstances. In particular, the Company may not be successful in its efforts commercialize or attain acceptable clinical results for its products. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts and research and development programs, uncertainties as a result of research and development, consumer and industry acceptance, litigation and/or court proceedings, regulatory risks including approval of Food and Drug Administration filings, the ability to achieve and maintain revenues and profitability in the Company�s business lines, and other factors discussed in the Company's filings with the Securities and Exchange Commission.